We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fresh from the Pipeline: Pegaptanib sodium.
- Authors
Fine, Stuart L.; Martin, Daniel F.; Kirkpatrick, Peter
- Abstract
In December 2004, pegaptanib sodium (Macugen; Eyetech/Pfizer), which targets vascular endothelial growth factor, was approved by the US FDA for the treatment of neovascular age-related macular degeneration. As well as being the first anti-angiogenic agent to be approved for this common eye disorder, it is also the first approved therapeutic based on an RNA structure known as an aptamer.
- Subjects
SODIUM; VASCULAR endothelial growth factors; EYE diseases; RETINAL degeneration; NERVOUS system; RNA
- Publication
Nature Reviews Drug Discovery, 2005, Vol 4, Issue 3, p187
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd1677